My Treatment Approach: HER2+ Breast Cancer - Episode 3

First-Line HER2+ Metastatic Breast Cancer Trials in Focus

, ,

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients
    EP. 2: Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape
    Now Viewing
    EP. 3: First-Line HER2+ Metastatic Breast Cancer Trials in Focus
    EP. 4: Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd
    EP. 5: Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates
    EP. 6: Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer
    EP. 7: TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
    EP. 8: Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches
    EP. 9: Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses
    EP. 10: Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches
    EP. 11: Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions
    x